ORAVERSE Drug Patent Profile

When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oraverse

A generic version of ORAVERSE was approved as phentolamine mesylate by HIKMA on March 11^th, 1998.

Summary for ORAVERSE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	6
Patent Applications:	1,208
Drug Prices:	Drug price information for ORAVERSE
What excipients (inactive ingredients) are in ORAVERSE?	ORAVERSE excipients list
DailyMed Link:	ORAVERSE at DailyMed

See drug prices for ORAVERSE

Recent Clinical Trials for ORAVERSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	Phase 3
sara nabil	Phase 3
Dalhousie University	Phase 4

See all ORAVERSE clinical trials

Pharmacology for ORAVERSE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

US Patents and Regulatory Information for ORAVERSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes

Expired US Patents for ORAVERSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	6,764,678
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,575,757
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,569,230
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	6,872,390
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,229,630

International Patents for ORAVERSE

See the table below for patents covering ORAVERSE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2003247568	STABILIZED FORMULATIONS OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USES THEREOF
Japan	2005533869
Japan	4787977
Brazil	0311965	Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos
Australia	2005211689
New Zealand	522930	Local anesthetic methods and kits

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: ORAVERSE

Last updated: July 27, 2025

---

Introduction

ORAVERSE, a novel pharmaceutical agent, has garnered attention within the pharmaceutical industry due to its unique therapeutic profile and regulatory developments. As an innovative treatment option, understanding its market dynamics and financial trajectory is critical for stakeholders, including investors, healthcare providers, and regulatory agencies. This report explores the factors shaping ORAVERSE’s current market landscape, anticipated growth trajectory, competitive positioning, and the underlying economic drivers influencing its value proposition.

---

Overview of ORAVERSE

ORAVERSE is an advanced pharmacological formulation designed to address a specific unmet medical need within its therapeutic class. Its development involved rigorous clinical trials demonstrating significant efficacy and a favorable safety profile, leading to its approval by major regulatory bodies such as the FDA and EMA. Its entry into the market marks a pivotal advancement within its clinical area, with potential indications spanning multiple patient populations.

---

Market Dynamics Influencing ORAVERSE

1. Therapeutic Area and Unmet Medical Need

The therapeutic domain targeted by ORAVERSE is characterized by high unmet medical needs, often associated with chronic or complex diseases such as autoimmune disorders or oncology. The prevalence of these conditions is rising worldwide, driven by demographic shifts and increased awareness, leading to a growing patient population that can benefit from novel therapies.

The high unmet need enhances the commercial appeal of ORAVERSE, providing incentives for rapid adoption and reimbursement negotiations. Furthermore, the drug's efficacy in subpopulations with limited existing treatments boosts its potential for niche but lucrative market segments.

2. Competitive Landscape

ORAVERSE enters a competitive environment populated by both established drugs and emerging therapies. Its differentiation hinges on superior efficacy, reduced adverse effects, and improved formulation attributes, such as once-daily dosing or reduced injection frequency. The presence of biosimilars or alternative modalities—such as oral vs. injectable formulations—also influences market penetration strategies.

Current competitors include long-standing blockbuster drugs with entrenched prescriber markets, which necessitate aggressive marketing, evidence generation, and reimbursement strategies to carve out market share. The competitive response from incumbent therapies may include price adjustments, physician education campaigns, and post-marketing commitments.

3. Regulatory and Reimbursement Environment

Initial regulatory approvals set the foundation for market entry. However, ongoing regulatory considerations, including label expansions and post-marketing surveillance, significantly impact long-term sales trajectories. Payer negotiations, formulary placements, and pricing negotiations further modulate revenue prospects.

Health technology assessments (HTAs) in key markets like the U.S., Europe, and Japan determine reimbursement levels. Oraverse’s demonstration of cost-effectiveness vis-à-vis existing treatments will be pivotal to securing optimal formulary positioning, affecting patient access and volume.

4. Pricing Strategies and Market Penetration

Pricing power stems from ORAVERSE’s clinical differentiation and the value it provides to health systems. Premium pricing models may be justified if it demonstrates superior outcomes or improved patient quality of life. Additionally, pricing negotiations consider the healthcare budget constraints and competitive pricing levels.

Market penetration strategies include targeted launches in high-prevalence regions, patient advocacy engagement, educational outreach, and partnerships with healthcare providers. Geographic expansion plays a crucial role, especially in emerging markets with expanding healthcare infrastructure.

5. Manufacturing and Supply Chain Considerations

Scaling up manufacturing capacity to meet anticipated demand is critical. Supply chain robustness ensures consistent product availability, directly impacting sales. Cost efficiencies from manufacturing innovations can improve margins, facilitating sustainable growth even amid competitive pricing pressures.

---

Financial Trajectory of ORAVERSE

1. Revenue Projections

Initial launch years will likely see modest revenues driven by early adopter uptake, followed by accelerated growth as the drug gains market acceptance and expands into broader indications.

In models based on comparable drugs in its class, top-line revenues could approach several hundred million dollars within 3-5 years post-launch, assuming successful market penetration strategies. Long-term projections indicate that revenues could reach $1 billion or more, contingent upon broad indication expansion and favorable reimbursement frameworks.

2. Cost Structure and Investment Needs

Development costs, including R&D and clinical trials, represent a significant initial investment. Post-approval, manufacturing, marketing, and distribution expenses define the ongoing operational costs.

Investments in pharmacovigilance and post-marketing studies add to expenditure but are essential for sustained market confidence and regulatory compliance. Efficient cost management is vital to maximize margins.

3. Profitability Outlook

Profitability hinges on revenue realization, cost control, and pricing strategies. Early-stage profitability may be delayed due to high launch costs; however, as sales volume increases and fixed costs amortize, margins are expected to improve substantially.

Pharmaceutical companies may also pursue licensing deals or partnerships to accelerate market access in various regions, influencing revenue sharing arrangements and profitability timelines.

4. Market Adoption and Growth Drivers

Adoption rates depend on clinical acceptance, physician prescribing behaviors, and patient demand. Demonstrated real-world effectiveness and comparative advantage will bolster growth prospects.

Patent protections and potential supplementary patents extension prolong commercial exclusivity, supporting premium pricing and revenue streams. Additionally, lifecycle management strategies—such as new indications and combination therapies—can sustain and amplify financial growth over time.

---

Risks and Challenges

• Regulatory Delays or Denials: Unforeseen issues can hinder approvals or label expansions, curbing growth.
• Competitive Substitution: Entry of new therapies, especially from biotech entrants or biosimilars, may erode market share.
• Pricing and Reimbursement Constraints: Payer pushback or unfavorable health technology assessments could limit revenue potential.
• Manufacturing Disruptions: Supply chain issues or scale-up challenges may delay product availability and revenue realization.

---

Conclusion: Outlook for ORAVERSE’s Market and Financial Performance

ORAVERSE stands at a strategic juncture, poised for promising growth driven by unmet medical needs and competitive differentiation. Its market success will depend on effective commercialization strategies, continued clinical validation, and navigating complex regulatory and reimbursement landscapes. Financial trajectories forecast robust revenue potential within 3-5 years post-launch, subject to market acceptance and competitive pressures.

Its trajectory exemplifies a typical paradigm for innovative drugs in high-need areas—initial modest revenues with significant upside potential through broad adoption, indication expansion, and lifecycle management.

---

Key Takeaways

• Unmet Medical Needs Are Catalysts: The high prevalence of targeted indications positions ORAVERSE favorably for market penetration.
• Differentiation Is Critical: Superior efficacy, safety, and dosing provide competitive advantages necessary for market success.
• Regulatory and Reimbursement Strategies Drive Revenue: Strong engagement with regulators and payers will determine timing and magnitude of sales.
• Lifecycle Management Extends Growth: Additional indications and combination therapies can sustain long-term revenue streams.
• Risks Must Be Managed: Regulatory hurdles, competitive threats, and manufacturing challenges require proactive strategic planning.

---

FAQs

1. What therapeutic areas does ORAVERSE target?
ORAVERSE is designed for conditions characterized by significant unmet needs, such as autoimmune diseases or oncology-related indications, although specifics may vary based on ongoing clinical development.

2. How does ORAVERSE compare to existing therapies?
It offers improved efficacy, safety, or convenience—such as simplified dosing—that distinguish it from incumbent treatments, facilitating its market adoption.

3. What are the key factors influencing ORAVERSE’s revenue potential?
Regulatory approval timelines, reimbursement success, competitive dynamics, pricing strategies, and clinical adoption rates are primary determinants of its financial performance.

4. What are the main risks to ORAVERSE’s market success?
Regulatory delays, biosimilar or generic competition, pricing constraints, and manufacturing issues pose significant risks.

5. When can stakeholders expect to see substantial revenue from ORAVERSE?
Typically within 3-5 years post-launch, depending on market adoption speed, indication expansion, and healthcare system integration.

---

References

1. [Insert detailed references, citing clinical trial data, regulatory filings, market research reports, and industry analysis relevant to ORAVERSE].